Dr. Lal Path Labs Ltd.

rs 31

mpany 70+ years of experience in the field of diagnostics 100 Mn patients serviced in last 5 years 31 NABL accredited Labs; National Reference Lab accredited by CAP Largest* diagnostics chain in the

20%

asis of revenue and presence Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl.

120%

s Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically sp

44%

ember 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 344 crore (Net

Rs. 344 crore

for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 344 crore (Net) Cash & Investments as on 31st Mar, 22 4,731 Patient Service Centres (PSC’s) 5,113 Patho

INR 2,087.4

ons, healthcare providers as well as hospital and clinical labs (lab management) FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1

INR 600.4

s as well as hospital and clinical labs (lab management) FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR

28.8%

nd clinical labs (lab management) FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr3 (Margin

INR 350.3

abs (lab management) FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr3 (Margin: 29.3%); PAT: INR

16.8%

FY22: Revenue: INR 2,087.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr3 (Margin: 29.3%); PAT: INR 296.5 Cr (Margin

INR 1,581.3

87.4 Cr.; EBITDA: INR 600.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr3 (Margin: 29.3%); PAT: INR 296.5 Cr (Margin: 18.8%); Classification: Res

INR 462.6

.4 Cr3 (Margin: 28.8%); PAT: INR 350.3 Cr (Margin: 16.8%); FY21: Revenue: INR 1,581.3 Cr.; EBITDA: INR 462.6 Cr3 (Margin: 29.3%); PAT: INR 296.5 Cr (Margin: 18.8%); Classification: Restricted 1. Total area

Managing Director said

1

Chief Executive Officer said

1

Chief Executive Officer said

the on “India remains a largely underserved market for diagnostics. The scope for growth for companies like ours is huge and we want to leverage our position as a leading player. At Dr. Lal PathLabs, we see ourselves as a progressive brand and have been at the forefront of integrating technology into our business model. This helps us reduce costs as well as provide a more seamless and cohesive experience to our latest patients. We continue to invest in technologies across medical science and patient service in line with out vision of being the most trusted healthcare partner” “The acquisition of Suburban Diagnostics has brought Dr. Lal PathLabs brand to the heart of Western market i.e., Maharashtra. And we will work with the Suburban team to leverage the joint expertise and capabilities to create best- top notch in-class proposition and deliver patient experience. We have demonstrated strong growth in this quarter, which is likely to continue as we realise our growth aspirations in var